Suppr超能文献

抗病毒治疗在大流行和呼吸道疾病(包括 COVID-19)暴发中的成本效益:已发表经济评估的系统综述。

Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.

机构信息

Faculty of Pharmacy, Clinical Pharmacy Department, Cairo University, Cairo, Egypt.

Accident and Emergency Department, North Middlesex University Hospital, London, UK.

出版信息

Value Health. 2020 Nov;23(11):1409-1422. doi: 10.1016/j.jval.2020.07.002. Epub 2020 Sep 6.

Abstract

OBJECTIVE

To review published economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses.

METHODS

We conducted a systematic review to identify economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses, including coronavirus disease 2019 (COVID-19). We searched Medline (EBSCOhost), EMBASE (Ovid), EconLit (Ovid), National Health Service Economic Evaluation Database (Ovid), and Health Technology Assessment (Ovid). The search was last rerun on July 5, 2020. Citation tracking and reference checking were used. Only full economic evaluations published as peer-reviewed articles in the last 10 years were included. Studies were quality assessed using the National Institute for Health and Care Excellence economic evaluation checklist.

RESULTS

Overall, 782 records were identified, of which 14 studies met the inclusion criteria. The studies were mostly conducted in high-income countries. All were model-based. Seven (50%) were cost-utility analyses, 4 (28.6%) were cost-effectiveness analyses, 2 (14.3%) were cost-consequences analyses, and 1 (7.1%) was a cost-benefit analysis. Strategies including antiviral treatment were found to be either cost-saving or cost-effective, at the study-specific willingness-to-pay thresholds. Empirical treatment was more cost-effective than test-guided treatment for young adults but less so for older adults.

CONCLUSIONS

Antiviral treatment for managing pandemics and outbreaks of respiratory illnesses that have very high case fatality rate, similar to COVID-19 pandemic, are likely to be cost-effective either as a standalone intervention or part of a multifaceted strategy. Investing in the development of such curative treatments and promptly evaluating their cost-effectiveness, relative to other strategies in use at the time of their introduction should be the focus going forward to inform resource allocation decisions particularly in low- and middle-income countries.

摘要

目的

综述抗病毒疗法治疗大流行和呼吸道疾病暴发的经济学评价。

方法

我们进行了系统综述,以确定抗病毒疗法治疗大流行和呼吸道疾病暴发(包括 2019 年冠状病毒病)的经济学评价。我们检索了 Medline(EBSCOhost)、EMBASE(Ovid)、EconLit(Ovid)、国家卫生服务经济评价数据库(Ovid)和卫生技术评估(Ovid)。检索最后一次更新日期为 2020 年 7 月 5 日。我们还使用了引文追踪和参考文献检查。仅纳入最近 10 年发表的作为同行评审文章的完整经济学评价。使用英国国家卫生与保健优化研究所经济评价清单对研究进行质量评估。

结果

共确定了 782 条记录,其中 14 项研究符合纳入标准。这些研究主要在高收入国家进行。所有研究均为基于模型的研究。7 项(50%)为成本效用分析,4 项(28.6%)为成本效果分析,2 项(14.3%)为成本后果分析,1 项(7.1%)为成本效益分析。在研究特定的意愿支付阈值下,包括抗病毒治疗在内的策略被发现具有成本节约或成本效益。对于年轻人,经验性治疗比基于检测的治疗更具成本效果,但对于老年人则不然。

结论

对于病死率非常高(类似于 2019 年冠状病毒病大流行)的大流行和呼吸道疾病暴发,抗病毒疗法作为单一干预措施或多方面策略的一部分,很可能具有成本效益。今后应将重点放在开发此类治疗方法上,并及时评估其相对于当时使用的其他策略的成本效益,这将有助于资源分配决策,尤其是在中低收入国家。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e7b/7474825/4abc3ff5d55b/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验